THE UTILIZATION OF VISUAL BASIC.NET APPLICATION FOR DETERMINATION OF INDIVIDUAL DRUG DOSAGES IN DIABETIC PATIENTS OF CHRONIC RENAL DISORDER COMPLICATIONS

Ari Usman; Nilsya Febrika Zebua

doi:10.22159/ajpcr.2018.v11s1.26616

Authors

Ari Usman Department of Informatics Engineering, Universitas Harapan Medan, Medan, Indonesia.
Nilsya Febrika Zebua Departmentof Pharmacy, Universitas Tjut Nyak Dhien, Medan, Indonesia

DOI:

https://doi.org/10.22159/ajpcr.2018.v11s1.26616

Keywords:

Visual BasicNet, Drug dosage, Pharmacokinetic calculations

Abstract

Â

Â Objective: This research aims to apply the Visual Basic.Net (VB.NET) of individual dose calculations based on the formula of pharmacokinetics for diabetic patients of chronic renal disorder complication in Dr. Pirngadi Hospital because the dosage administered was not based on the patient's creatinine clearance.

Methods: This descriptive research was conducted using a simulated creatinine cleavage calculation using VB.NET programming language applications with variable patient data, the value of creatinine, the name of drug, and dosage.

Results: This study obtained data about the use of drugs 40 patients who met the inclusion criteria of 320 medical records of diabetic patients, there are 6 types of drugs that are not in accordance with the dose based on the calculation of creatinine clearance are ceftriaxone(18 of 18 cases), furosemide (19 of 19 cases), ciprofloxacin (2 of 8 cases), ranitidine (4 of 24 cases), metformin (2 of 7 cases), and captopril (16 of 16 cases).

Conclusions: This research aims to apply the VB.NET is it able to apply individual doses for patients with diabetes complications of renal failure have not been applied in accordance with creatinine clearance calculations at this hospitalwhere this work is difficult to do.

Downloads

Download data is not yet available.

References

Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Polsey M. Pharmacotherapy a Pathophysiologic Approach. 7th ed. New York: McGraw-Hill; 2008. p. 475-507.

Shargel L, Wu-Pong S, Yu AB. Applied Biopharmaceutics and Pharmacokinetics. 5th ed. United States: The McGraw-Hill Companies; 2005.

Bauer LA. Clinical Pharmacokinetics Handbook. Washington, DC: McGram Hill; 2006.

Hewlet T. Nephrotoxic drug. Can Fam Phycisian 2004;50:709-11.

Falconnier AD, Haefeli WE, Schoenenberger RA, Surber C, Martin-Facklam M. Drug dosing in patient with renal failure optimized by immediate concurrent feedback. J Glob Inform Manag 2001;16:369-75.

Munar MY, Singh H. Drug dosing adjustment in patients with chronic kidney disease. Am Acad Fam Physician 2007;75:1487-96.

Faull FR. Prescribing in renal disease. Aust Prescr 2007;30:17-20.

Patel M, Patel N, Nirmit S. Introduction to new features of visual basic 2010. Int J Adv Eng Technol 2010;1:10-5.

Usman A, Zebua NF. Design of individual dosing individual drawing applications using visual basic net programming based on pharmacokinetics data calculation. Sync J Inform Eng Res 2017;2:44-8.

Sweetman SC. Martindale. The Complete Drug Reference. 36th ed. United States: The Phamaceutical Press; 2009.

Olivera ME, Manzo RH, Junginger HE, Midha KK, Shah VP, Stavchansky S. Biowaiver monographs for immediate release solid oral dosage forms: Ciprofloxacin hydrochloride. J Pharm Sci 2010;10:1-12.

Brater DC. Diuretic therapy. N Engl JMed 1998;339:387-95.

Siu-Kim C, Chan LK. Drug Dose in Patient with Rena Impairment. In: Lai KN, editor. A Practical Manual of Renal Medicine. Hongkong: World Scientific; 2009.

Patel IH, Sugihara JG, Weinfeld RE, Wong EG, Siemsen AW, Berman SJ. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob Agents Chemother 1984;25:438-42.

Drummer OH, Workman BS, Miach PJ, Jarrot B, Louis WJ. The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patientson maintenance dialysis: Comparison with patients with normal renal function. Eur J Clin Pharmacol 1987;32:267-71.